尊龙凯时

The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.

More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.

The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.

The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, China.

The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.

While building a first-class platform for R&D and innovation, the company provides all-around service from research, development, and clinical trials to registration of new drugs.

The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.

Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and 7 experts enjoying a special allowance of The State Council.